Zydus Group

zyduscadila.com

Zydus is an innovation-led global healthcare provider that discovers, manufactures and markets a broad range of healthcare therapies. The group employs over 19,000 people worldwide including over 1200 scientists engaged in research and is dedicated to creating healthier communities globally.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

TARSIER PHARMA RAISES CAPITAL TO EXECUTE PHASE-3 CLINICAL TRIAL

Tarsier Pharma | August 28, 2021

news image

Tarsier Pharma, a late clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, today announced it raised capital to execute a phase-3 clinical trial of its TRS01 program in the US and Europe. Strategic and new investors alongside existing investors participated in this transaction. Following a successful End of Phase II meeting with the FDA, the Company obtained all necessary regu...

Read More

Business Insights

CEDARS-SINAI MEDICAL CENTER AND AIKIDO PHARMA INC. TO CODEVELOP NOVEL IMMUNO-ONCOLOGY CANCER TREATMENT

AIkido Pharma Inc. | March 15, 2022

news image

AIkido Pharma Inc. announced that the Company and Cedars-Sinai Medical Center have agreed under their Master Collaboration Agreement to co-fund and codevelop a novel immuno-oncology treatment designed to promote the destruction of cancer cells by a patient's own "killer" T-cells. The Company and Cedars-Sinai will share costs, expenses and management of the drug co-development and will leverage the talent of Cedars-Sinai Technology Ventures and the lead scientists who...

Read More

Research

ROIVANT GROWS COMPUTATIONAL DRUG DISCOVERY ENGINE WITH ACQUISITION OF SILICON THERAPEUTICS

Roivant Sciences | March 01, 2021

news image

Silicon Therapeutics has assembled an exclusive industry-driving computational physics platform for the in silico design and optimization of small molecule drugs for testing disease targets. The platform incorporates custom strategies dependent on quantum mechanics, sub-atomic elements and measurable thermodynamics to beat basic bottlenecks in drug disclosure projects, for example, anticipating restricting energies and conformational conduct of molecules. Silicon Therapeutics'...

Read More

ANTI-PARASITIC DRUG SAID TO 'KILL' COVID-19 CELLS

Alcoholics Anonymous | April 09, 2020

news image

Scientists in Australia have found that an anti-parasitic drug available on the market “can kill” the growing cell culture of the deadly coronavirus within 48 hours. However, researchers say the drug cannot be used in humans for COVID-19 until further testing and clinical trials prove its safety and effectiveness. “Scientists showed that a single dose of the drug, Ivermectin, could stop the SARS-CoV-2 [COVID-19] virus growing in cell culture,” said a statement by Melbourn...

Read More
news image

Pharmacy Market

TARSIER PHARMA RAISES CAPITAL TO EXECUTE PHASE-3 CLINICAL TRIAL

Tarsier Pharma | August 28, 2021

Tarsier Pharma, a late clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, today announced it raised capital to execute a phase-3 clinical trial of its TRS01 program in the US and Europe. Strategic and new investors alongside existing investors participated in this transaction. Following a successful End of Phase II meeting with the FDA, the Company obtained all necessary regu...

Read More
news image

Business Insights

CEDARS-SINAI MEDICAL CENTER AND AIKIDO PHARMA INC. TO CODEVELOP NOVEL IMMUNO-ONCOLOGY CANCER TREATMENT

AIkido Pharma Inc. | March 15, 2022

AIkido Pharma Inc. announced that the Company and Cedars-Sinai Medical Center have agreed under their Master Collaboration Agreement to co-fund and codevelop a novel immuno-oncology treatment designed to promote the destruction of cancer cells by a patient's own "killer" T-cells. The Company and Cedars-Sinai will share costs, expenses and management of the drug co-development and will leverage the talent of Cedars-Sinai Technology Ventures and the lead scientists who...

Read More
news image

Research

ROIVANT GROWS COMPUTATIONAL DRUG DISCOVERY ENGINE WITH ACQUISITION OF SILICON THERAPEUTICS

Roivant Sciences | March 01, 2021

Silicon Therapeutics has assembled an exclusive industry-driving computational physics platform for the in silico design and optimization of small molecule drugs for testing disease targets. The platform incorporates custom strategies dependent on quantum mechanics, sub-atomic elements and measurable thermodynamics to beat basic bottlenecks in drug disclosure projects, for example, anticipating restricting energies and conformational conduct of molecules. Silicon Therapeutics'...

Read More
news image

ANTI-PARASITIC DRUG SAID TO 'KILL' COVID-19 CELLS

Alcoholics Anonymous | April 09, 2020

Scientists in Australia have found that an anti-parasitic drug available on the market “can kill” the growing cell culture of the deadly coronavirus within 48 hours. However, researchers say the drug cannot be used in humans for COVID-19 until further testing and clinical trials prove its safety and effectiveness. “Scientists showed that a single dose of the drug, Ivermectin, could stop the SARS-CoV-2 [COVID-19] virus growing in cell culture,” said a statement by Melbourn...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us